Loading...
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M. Tomasson, M. H. Arnulf, B. Bahlis, N. J. Miles Prince, H. Niesvizky, R. Rodrίguez-Otero, P. Martinez-Lopez, J. Koehne, G. Touzeau, C.
Lesokhin, A. M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Miles Prince, H.
Niesvizky, R.
Rodrίguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Touzeau, C.
Citations
Altmetric:
Abstract
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3-4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3-4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy.
Authors
Lesokhin, A. M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Miles Prince, H.
Niesvizky, R.
Rodrίguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Touzeau, C.
Jethava, Y.
Quach, H.
Depaus, J.
Yokoyama, H.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Manier, S.
Raje, N.
Iida, S.
Raab, M. S.
Searle, Emma
Leip, E.
Sullivan, S. T.
Conte, U.
Elmeliegy, M.
Czibere, A.
Viqueira, A.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Miles Prince, H.
Niesvizky, R.
Rodrίguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Touzeau, C.
Jethava, Y.
Quach, H.
Depaus, J.
Yokoyama, H.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Manier, S.
Raje, N.
Iida, S.
Raab, M. S.
Searle, Emma
Leip, E.
Sullivan, S. T.
Conte, U.
Elmeliegy, M.
Czibere, A.
Viqueira, A.
Mohty, M.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature medicine. 2023 Aug 15. PubMed PMID: 37582952. Epub 2023/08/16. eng.